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Abstract. The present study aimed to assess the diagnostic/ 
prognostic value of various clinical tumor markers, including 
carcinoembryonic antigen (CEA), neuron-specific enolase 
(NSE), cytokeratin 19 (CYFRA21-1), α-fetoprotein (AFP), 
carbohydrate antigen-125 (CA-125), carbohydrate antigen-
19.9 (CA-19.9) and ferritin, individually or in combination. 
The electro-chemiluminescence immunization method was 
performed to detect the levels of seven tumor markers in 
560 cancer patients and 103 healthy subjects for comparison. 
The serum levels of the seven markers measured in cancer 
patients were higher compared to healthy subjects (P<0.05 for 
AFP and P<0.001 for the remaining six markers). Different 
markers had different sensitivity towards different types of 
tumors. Combining more markers significantly increased 
the ratios of positive diagnosis in the tumors. The diagnostic 
sensitivities of combining seven markers were particularly 
high in digestive, urinary and skeletal tumors (82, 92 and 83%, 
respectively). Gynecological tumors have exhibited a constant 
yet relatively low positive diagnosis irrespective of the use of 
a single marker or combined markers. However, the increase 
in sensitivity when combining markers was accompanied by 
a decrease in specificity. Generally, combining more markers 
increased the tumor detection rates, while a combination of the 
seven markers provided the highest detection rate. Combined 
detection showed a particularly high sensitivity in detecting 
respiratory, digestive and urinary system tumors, with the 
lowest sensitivity observed in gynecological tumors. As a 
result, combining tumor markers may play an important role 
in early tumor detection/diagnosis while the loss of specificity 
can be tolerated.
Introduction
Early diagnosis is known to lead to successful treatment of 
cancer (1). However, many patients are still diagnosed with late 
stage cancer when they seek medical care, and therefore do not 
receive effective treatment. Diagnosis of the disease merely by 
symptoms and physical signs is limiting, and the detection of 
tumors without any early signs is extremely difficult. Obtaining 
tissues for biopsy is a method employed for final diagnosis. 
However, this method cannot be readily repeated, as tissue 
biopsy causes physical harm to the patient. Moreover, unless 
presented with evidence of a high probability of having cancer, 
patients are also reluctant to undergo biopsy. Therefore, an 
emphasis has been placed on tumor markers and their role in 
assisting with screening and diagnosing tumors (2-5). Certain 
tumor markers are detected in serum when tumors are at an 
early stage, rendering the identification of tumor markers an 
area of interest.
A number of tumor diagnostic biomarkers have been 
identified and developed, a number of which have been widely 
adopted in the screening and diagnosis of cancer. Studies have 
focused on carcinoembryonic antigen (CEA) for over 40 years 
(6), suggesting it be a useful tool in the diagnosis of cancer (7), 
as it is a cancer cell adhesion marker (8,9). The neuron-specific 
enolase (NSE) is a highly specific marker for neurons (10), 
with its serum level being a potentially useful marker for the 
detection of tumors of neuronal origin (11,12). Cytokeratin 19 
(CYFRA21-1) is another useful tumor marker employed in the 
diagnosis of various types of cancer (13-15), and is particularly 
sensitive in adenocarcinomas in the gastrointestinal tract and 
pancreas (13,16). Since the 1970's, the α-fetoprotein (AFP) 
marker has been used mainly to detect gastrointestinal and 
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hepatic cancer (2,17). Combined with ultrasonography, AFP 
is the most common clinical approach to diagnosing hepa-
tocellular carcinoma (18). Serum carbohydrate antigen-125 
(CA-125) and carbohydrate antigen-19.9 (CA-19.9) are also 
commonly used biomarkers in the screening of various types 
of cancer (19-21), and are particularly sensitive to cancer in the 
digestive system (22-24). Ferritin is another commonly used 
clinical cancer biomarker, as cancer may alter the whole body 
iron metabolism, occasionally reflected in the change of the 
serum ferritin levels (25,26).
The above-mentioned tumor markers exhibit various sensi-
tivities against various types of cancer. Generally, each marker 
has a relatively low sensitivity, albeit a reasonable specificity 
towards certain types of cancer (4). Since these tumor markers 
can be measured using electrochemiluminescence immuniza-
tion, a combination of these tumor markers is likely to improve 
the clinical tumor diagnostic sensitivity. In the present study, 
various combinations of the seven tumor markers were exam-
ined and the clinical diagnostic values of those combinations 
were assessed.
Materials and methods
Patient cohorts. This study was approved by the Human Ethics 
Committee of Xi'an Jiaotong University. In total, 560 malignant 
tumor cases from out- and inpatients of the First Hospital of the 
Xi'an Jiaotong University were gathered between June, 2008 
and December, 2009. The patients were firmly diagnosed using 
pathohistological methods. The number of patients and tumor 
types are listed in Table I. None of the subjects showed severe 
damage of other organs, had diabetes, hypertension, or dysfunc-
tion of the heart, liver or kidney. The control group comprised 
103 healthy idividuals (44 males and 59 females; median age, 
55.3 years) who underwent physical examination at the hospital.
Detection method. Peripheral blood (2.0 ml) was collected in 
a vacuum tube (BD Biosciences, Franklin Lakes, NJ, USA) 
without hematolysis or lipemia from each participant after 
overnight fasting. Each sample was centrifuged at 1,710 x g 
for 5 min at 4˚C. The serum was separated from the sample 
following centrifugation, and kept at 4˚C until analysis. The 
assays were performed within 5 days after samples were 
obtained. Electrochemiluminescence immunization (Roche 
Cobas e601) was applied to evaluate the seven tumor markers.
Assessment of the results. The values in the assay kits 
provided by the manufacturers were accepted as the 
clinical cut-off values. The cut-off values of the markers 
were as follows: CEA <3.4 ng/ml, CA-125 <35 U/ml, 
CA-19.9 <39 U/ml, AFP <7.02 ng/ml, CYFRA21-1 <3.3 ng/ml, 
30 ng/ml < ferritin <400 ng/ml and NSE <15.2 µg/l. The upper 
bound of the normal value was the critical value. When the 
value was higher than the critical value, it was considered to 
be positive (indicating the presence of tumor). We used ‘a’ to 
represent the true positive value; ‘b’, the false positive value; 
‘c’, the false negative value and ‘d’, the true negative value. The 
sensitivity was calculated using the formula: a/(a+c) x 100%, 
while the specificity was calculated as d/(b+d) x 100%. When 
combining tumor markers, a positive in any marker was 
considered to be overall positive.
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Statistical analysis. Statistical analysis was performed using 
the SPSS v13.0 software. P<0.05 was considered to indicate 
a statistically significant difference. The median value was 
taken, since some of the data exceeded the standard curve 
end values and the tumor marker levels did not show normal 
distribution. The χ2 test was used to compare the ratio.
Results
Levels of serum tumor markers in subjects with and without 
cancer. The serum levels of the seven tumor markers in subjects 
with and without tumors are listed in Table II. The serum 
levels of the seven tumor markers were significantly higher 
compared to the healthy controls with all P-values <0.001, with 
the exception of the P-value of AFP, which was <0.05 (0.037).
Diagnostic efficiency in various tumors. The positive ratios of 
the seven tumor markers in cancer patients were significantly 
higher compared to the healthy subjects, with P-values <0.001, 
with the exception of AFP, which was 0.002 (Table III). The 
positive ratios of tumor markers in the various groups of 
tumors were significantly different (P<0.05). The detection 
rates of CYFRA21-1, CEA, NSE and CA-125 were relatively 
high in the respiratory system tumor group (>40%); in the 
digestive system tumor group (CA-19.9, CEA and CYFRA21-1) 
(>40%) and in the urinary system tumor group (CA-125) 
(50%). However, the number of tumor cases was relatively 
low (only 12), whereas CYFRA21-1 and NSE in the skeletal 
system tumor group had relatively high detection rates (>40%) 
(Table III). The false positive rates of the seven tumor markers 
in different tumor groups were 1.0-11.8% (Table III).
Combining tumor markers in diagnosis. Tumor markers 
were combined to increase detection sensitivity. Different 
combinations of tumor markers were assessed and sensitivities 
detected (Table IV). Generally, with an increased number of 
tumor markers, the detection sensitivity increased (Table IV). 
However, increased sensitivity also meant decreased speci-
ficity (Table IV). The highest sensitivity (97.6%) was achieved 
by combining six tumor markers (CEA, NSE, CYFRA21-1, 
CA-125, CA-19.9 and ferritin) in respiratory system tumors. 
Adding the seventh marker, AFP, did not increase the sensi-
tivity. However, the specificity was low for such a six-marker 
combination (65.7 or 67/102), meaning 35 out of 102 healthy 
individuals could be identified as potential cancer patients. In 
the digestive system tumors, urinary system tumors and bone 
cancers, the detection rates were also high when the seven 
tumor markers were combined (82.2, 90.9 and 83.3%, respec-
tively). However, the specificity for such a combination was 
only 64.7% (Table IV).
Tumor markers in different tumors. Tumors in different systems 
were identified, and the detection rates of the tumor markers for 
those tumors are shown in Table V. CYFRA21-1 was the best 
predictor for lung squamous cell carcinoma, with an 83.33% 
positive rate. CA-19.9 was the best predictor for gallbladder 
carcinoma, with a 71.43% positive rate. CEA was the best 
predictor for pancreatic cancer, with a 61.54% positive rate. The 
worst prediction rates of the seven tumor markers were evident 
mainly in cervical cancer and carcinoma of the fallopian tube.
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Discussion
Seven serum tumor markers were measured in 560 cancer 
patients and 103 healthy volunteers to study the sensitivity and 
specificity of these markers. Findings showed that different 
markers had different detection sensitivities in different groups 
of tumors. Combining tumor markers significantly increased 
the detection sensitivity, while markedly decreasing specificity.
Results of the present study have shown that, as a single 
marker, the CEA-positive ratio is the highest in respiratory 
system tumors, at 46.2% (Table III), while according to 
specific tumors analyzed, CEA in pancreatic cancer exhib-
ited the highest sensitivity, at 61.5% (Table V). However, the 
detection sensitivity of CEA was found to be relatively low in 
the urinary system and gynecological tumors (8.3 and 6.4%, 
respectively). The specificity of CEA in this study was shown 
to be relatively good, reaching 96.1% (false-positive rate 3.9%)
(Table III). Previous studies have shown that CEA levels are 
elevated in 0-38% limited-stage small cell lung cancer (SCLC) 
patients and 40-65% in extensive-stage SCLC patients (27), 
as well as in 30-65% of non-SCLC patients (28). Results of 
another study have demonstrated that CEA levels were altered 
in glandular cancer with a high positive ratio and specificity 
(29). However, CEA has also been shown to be elevated 
in some benign tumors and non-tumor diseases, including 
hepatic cirrhosis, colonic polyp, smoking and pregnancy (30). 
Therefore, the specificity of CEA poses a problem. However, 
in this study, individuals  with other diseases were excluded 
from our healthy volunteer group, resulting in a high speci-
ficity (Table III).
Results showed the positive ratio of CYFRA21-1 to be the 
highest in respiratory system tumors in this study, especially in 
lung squamous cell carcinoma (Table V). This ratio is also high 
in bone cancers and tumors of the digestive system. Therefore, 
it may be considered as an index for the early diagnosis of 
lung cancer, osteocarcinoma and digestive system tumors. 
CYFRA21-1 is widespread in epithelial cells (31). When 
epithelial cells malignantly transform, an activated protease 
accelerates the degradation of keratin and a large amount of 
keratin dissolvable CYFRA21-1 fragments is released into the 
blood circulation, thus the serum concentration of CYFRA21-1 
increases (32). CYFRA21-1 has been reported to be higher in 
patients with squamous cell carcinoma compared to patients 
with glandular and SCLC (33).
The positive ratio of CA-19.9 is the highest in digestive 
system tumors, followed by urinary system tumors. Specifically, 
the carcinoma of the gallbladder shows the highest sensitivity, 
while other system tumors show low sensitivity (Table V). Our 
data indicate that CA-19.9 may be used as a clinical index for 
the early diagnosis of digestive system and urinary system 
tumors. In the literature, there are suggestions that CA-19.9 be 
considered a good marker for pancreatic cancer (34), which is 
inconsistent with our results, where the positive rate of CA-19.9 
in pancreatic cancer was relatively high, at 57.7% (Table V).
Findings of this study indicate that the positive ratio and 
serum level of NSE are the highest in respiratory system 
tumors (Tables II and III), while in the digestive system and 
breast tumor groups, NSE sensitivity is low. As an isozyme of 
enolase, NSE has been confirmed by a large amount of clinical 
data to be the most valuable tumor marker for SCLC, and is 
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considered the most sensitive and specific marker for SCLC 
(35). In our study, the detection rate of NSE in SCLC is one of 
the highest among the seven markers and the highest compared 
to NSE in other types of tumors (58.3%) (Table V). However, 
the specificity is low in our study, with the false-positive ratio 
reaching 10.3% (Table III).
Our study has shown that the positive ratios of ferritin are 
not high in tumors of all the systems. This may be due to the 
fact that ferritin is present in various tissues and inflamma-
tion may elevate its level. Therefore, it may not be valuable 
in diagnosing tumors alone, but should be considered as an 
assistant reference index. Synthesizing and enriching in the 
liver, a large amount of ferritin is released when liver cells are 
damaged or destroyed due to liver diseases or tumors. Since the 
response is not tumor-specific, the specificity is generally low 
(36). In recent years, ferritin has been found to be synthesized 
and secreted by several entity malignant tumors, thus it may 
be considered an auxiliary diagnostic criterion for malignant 
tumors. Early literature suggests that the serum ferritin level 
in patients with leukemia, Hodgkin's disease, breast cancer, 
ovarian cancer and colon carcinoma markedly increases and is 
correlated with the degree of the disease (37,38). In our study, 
the specificity of ferritin in healthy volunteers was high with 
the false-positive ratio, reaching only 2.9% (Table III). This 
finding may be because only healthy subjects were studied and 
individuals with other liver diseases were excluded.
In our study, urinary system tumors have the highest 
CA-125-positive  detection ratio, followed by the respiratory 
system tumors. This finding may be considered a diagnostic 
index for tumors of the respiratory and the urinary system. 
However, previous studies have raised doubts regarding the 
specificity of CA-125 in malignant tumors, as it is present 
in the mammary gland, the lung and benign and malignant 
effusions (39,40). Another study has indicated that the sensi-
tivity and specificity of CA-125 in diagnosing early ovarian 
cancer are 72 and 95%, respectively (41). Apart from ovarian 
tumors, CA-125 has also been confirmed to have a high 
positive detection ratio in lung cancer patients (11). CA-125 
is expressed in ~51% of lung cancer tissues, and the level is 
closely correlated with the differentiated degree of tumors 
(42). In non-SCLC patients, the CA-125 level is elevated, 
especially in advanced-stage patients (43). In our study, the 
CA-125-positive detection ratio appeared to be high (>40%) 
in lung squamous cell carcinoma, lung adenocarcinoma, 
SCLC, colon and liver cancer, gall bladder carcinoma and 
ovarian cancer (Table V). The positive ratio of CA-125 in 
ovarian cancer was found to be the highest among seven 
markers, suggesting that it may be used for the diagnosis of 
ovarian cancer. However, the specificity of CA-125 in our 
results was relatively low, with an 8.8% false-positive ratio in 
the healthy controls (Table III).
In this study, the positive ratio of AFP was the highest in 
digestive system tumors, especially in liver cancer. The detec-
tion ratio in liver cancer was significantly higher compared to 
any other type of tumor. This is inconsistent with the literature, 
where AFP is considered to be the specific diagnosis index for 
liver cancer (44). When combined with other markers, AFP 
sensitivity increases significantly (44). However, AFP also 
elevates in non-tumor diseases, such as acute and chronic 
hepatitis and cirrhosis (45).
In our study, CEA+CYFRA21-1 shows a higher overall 
sensitivity compared to any other two-marker combinations. 
CEA+CA-125 shows the highest sensitivity in urinary system 
tumors, while the sensitivity of CEA+CYFRA21-1 is the highest 
in breast tumors. In bone cancer, CEA+NSE shows the highest 
sensitivity. In the digestive system tumors, the sensitivity of 
CEA+CA-19.9 is the highest compared to the other two-marker 
combinations. Furthermore, the specificity of CEA+CA-19.9 in 
healthy subjects is high, rendering this combination a favorable 
option for the diagnosis of digestive tumors. Since the three-
marker combination does not significantly increase sensitivity, 
the CEA+CYFRA21-1 and CEA+CA-19.9 combination may be 
more valuable in the clinical diagnosis of tumors in the respi-
ratory and the digestive system. However, the present study 
includes only limited cases, thus additional large-scale studies 
are needed to explore/confirm the diagnostic potential of those 
markers and combinations.
A combination of more markers, leads to an increase in 
the detection rate. Results of the present study have shown 
that combining seven markers yields the highest detection 
ratios, i.e., 97.6, 82.1, 72.7, 90.9, 83.3 and 45.4%, in respiratory 
and digestive system tumors, breast cancer, urinary system 
tumors, bone cancer and gynecological tumors, respectively. 
It appears that the seven-marker combination provides a high 
sensitivity in detecting tumors in the respiratory, digestive, 
urinary and bone systems. However, the combination of 
seven markers to detect tumors compromises specificity. The 
lowest specificity of a single marker is 88.2% (CYFRA21-1). 
The combination of seven markers resulted in the decrease 
of specificity to 64.7% (Table IV). This renders combination 
markers less useful in detecting breast cancer and gyneco-
logical tumors, where combined sensitivity is only 72.7 and 
45.4%, respectively. No statistically significant difference was 
detected between the ratios of false-positive and true-positive. 
The decrease in specificity raises doubt regarding the useful-
ness of the serum marker combination in tumor diagnosis, even 
for detecting tumors with high sensitivity. With the inpatient 
number of the oncology department reaching ~5,000/year in 
our hospital, the potential false-positive number would have 
been significant, should such seven-marker combination be 
used for patient diagnosis. Thus, the combination of multiple 
markers in diagnosis may be more suitable for patients with 
suspected tumors.
In conclusion, due to the complexity of the tumor origin 
and the heterogeneity of the tumor antigen expression, a single 
tumor marker may not be able to sufficiently detect tumors 
in certain cases. The combination of several markers may be 
helpful to improve diagnosis. However, a decreased specificity 
is an issue that needs to be addressed when employing such 
an approach. Considering the diversification of the biological 
behavior of tumor cells and the possibility of heterogenization 
in the course of treatment, tumor markers should be combined 
and detected repeatedly, in order that they more closely reflect 
the oncocytology and improve diagnostic efficiency.
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